These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 9510119)

  • 21. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. II. Clinical significance of measuring TSAb and TBII in patients with euthyroid Graves' disease and patients with hyperthyroid Graves' disease during antithyroid drug treatment].
    Uno C; Nishikawa M
    Nihon Naibunpi Gakkai Zasshi; 1988 Mar; 64(3):206-15. PubMed ID: 2456230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.
    Bliddal H; Bech K; Siersbaek-Nielsen K; Friis T
    J Endocrinol Invest; 1983 Aug; 6(4):259-62. PubMed ID: 6139399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyroid stimulating immunoglobulins in patients in long-term remission after Graves' disease.
    Bliddal H; Bech K; Kirkegaard C
    Horm Metab Res; 1984 Nov; 16(11):602-5. PubMed ID: 6210237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs.
    Massart C; Orgiazzi J; Maugendre D
    Clin Chim Acta; 2001 Feb; 304(1-2):39-47. PubMed ID: 11165197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
    Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
    Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease.
    Feldt-Rasmussen U; Schleusener H; Carayon P
    J Clin Endocrinol Metab; 1994 Jan; 78(1):98-102. PubMed ID: 8288723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease.
    Kasagi K; Hatabu H; Tokuda Y; Iida Y; Endo K; Konishi J
    Clin Endocrinol (Oxf); 1988 Oct; 29(4):357-66. PubMed ID: 2908031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y; Takeoka K; Amino N
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication.
    Smith J; Brown RS
    Thyroid; 2007 Nov; 17(11):1103-7. PubMed ID: 17822376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J; Gao H; Xu L
    Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):218-20, 254-5. PubMed ID: 7922762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Change of circulating thyroid autoantibody titers in Graves' hyperthyroidism after antithyroid drugs therapy.
    Lin HD; Tai FT; Chen HD; Lee SP; Chang FY; Wang GG; Tang KT; Lee JK
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Feb; 47(2):86-90. PubMed ID: 1705860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antithyrotropin receptor antibodies in a series of Basedow's disease].
    Vidal E; Antoine E; Nadalon S; Cevallos R; Bournaud E; Vandroux JC; Bordessoule D; Loustaud V; Weinbreck P; Liozon F
    Ann Med Interne (Paris); 1988; 139(5):331-5. PubMed ID: 2462393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.